Colesevelam hydrochloride
The DOI matches its Crossref record.
Abstract
The pharmacology, pharmacodynamics, clinical efficacy, drug interactions, adverse effects, and dosage and administration of colesevelam hydrochloride are reviewed. Colesevelam hydrochloride is a nonabsorbed lipid-lowering agent approved for use alone or in combination with hydroxymethylglutaryl-coenzyme A (HMG-CoA) reductase inhibitors for the reduction of low-density-lipoprotein (LDL) cholesterol in patients with primary hypercholesterolemia. Colesevelam forms nonabsorbable complexes with bile acids in the gastrointestinal (GI) tract, resulting in changes in plasma lipid levels, including total, LDL, and high-density-lipoprotein cholesterol and triglycerides. Colesevelam has been reported to be four to six times as potent as traditional bile acid sequestrants (BASs), perhaps because of its greater binding affinity for glycocholic acid. Unlike cholestyramine and colestipol, colesevelam appears to reduce LDL cholesterol in a dose-dependent manner. In clinical trials, colesevelam demonstrated efficacy either alone or in combination with HMG-CoA reductase inhibitors in the treatment of primary hypercholesterolemia. Combination therapy appeared to be more effective than monotherapy. Although infection, headache, and GI adverse effects have been reported for colesevelam, the rates do not differ significantly from those occurring with placebo. The constipation that typically hinders compliance with traditional BASs is minimal. In one study, the rate of compliance with colesevelam was 93%. There is little evidence of clinically significant interactions involving colesevelam. The maintenance dosage is three 625-mg tablets twice daily or six tablets once daily, taken with meals. Colesevelam provides an effective alternative to cholestyramine and colestipol while offering the potential for fewer adverse effects and better compliance. Studies are needed to directly compare colesevelam with traditional BASs.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Camilleri, M., Nadeau, A., Tremaine, W. J., Lamsam, J., Burton, D., Odunsi, S., Sweetser, S., & Singh, R. (2009) · Neurogastroenterology & Motility · doi:10.1111/j.1365-2982.2009.01288.x · Cited by 153
Kuiper, E. M. M., van Erpecum, K. J., Beuers, U., Hansen, B. E., Thio, B. H., de Man, R. A., Janssen, H. L. A., & van Buuren, H. R. (2010) · Hepatology · doi:10.1002/hep.23821 · Cited by 132
Quantifying bile acid malabsorption helps predict response and tailor sequestrant therapy
Orekoya, O., McLaughlin, J., Leitao, E., Johns, W., Lal, S., & Paine, P. (2015) · Clinical Medicine · doi:10.7861/clinmedicine.15-3-252 · Cited by 74
Colesevelam hydrochloride and lanthanum carbonate interfere with the absorption of levothyroxine
Weitzman, S. P., Ginsburg, K. C., & Carlson, H. E. (2009) · Thyroid · doi:10.1089/thy.2008.0312 · Cited by 35
Metadata
- Authors
- Steinmetz, K. L.
- Venue
- American Journal of Health-System Pharmacy
- Publisher
- Oxford University Press (OUP)
- Published
- 2002-05-15
- Volume
- 59
- Issue
- 10
- Pages
- 932-939
- ISSN
- 1079-2082 (ISSN-L)
- 1535-2900
- OpenAlex
- W4239263566
- Cited by
- 53
- References
- 0
- FWCI
- 4.23
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Colesevelam hydrochloride. https://app.cochat.ai/papers/10.1093/ajhp/59.10.932
- The paper
- Steinmetz, K. L. (2002). Colesevelam hydrochloride. American Journal of Health-System Pharmacy. https://doi.org/10.1093/ajhp/59.10.932
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.